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Introduction: The only treatment for aseptic loosening is the replacement of the prosthesis
through revision surgery. A preventive approach, achieved through anti-inﬂammatory drugs
released from the device, has shown to be a viable strategy; however, the performance of
these devices is not yet satisfactory thus further improvements are necessary.
Methods: We used titanium nanoparticles as a model for implant surfaces and developed a
coating containing dexamethasone (DEX) using layer-by-layer deposition.
Results: The amount of deposited drug depended on the number of layers and the release
was sustained for months. The efﬁciency of the released DEX in reducing inﬂammation
markers (tumor necrosis factor alpha and IL-6) produced by human monocytes and macro-
phages was similar to the pure drug at the same concentration without negative impacts on
the viability and morphology of these cells.
Conclusion: These coatings were not inferior to medical grade titanium (the standard material
used in uncemented devices) regarding their ability to sustain osteoblasts and ﬁbroblasts growth.
Keywords: titanium, cementless prosthesis, aseptic loosening, dexamethasone
Introduction
Sixty-eight thousand primary hip and 71 thousand knee replacement procedures
were performed by the National Health Service in England and Wales in 2017.1 It is
expected that these operations will be performed on an increasing number of
patients because of the improvement in life quality they provide and the constantly
aging population. The joint replacement device can be ﬁxed to the adjacent bone
tissue through two main methods; either using bone cement or cementless ﬁxation
which aims to the direct integration of the implant with the host tissue.
Cementless ﬁxation requires a shorter time in the operating room, allows greater
preservation of bone stock and provides easer revision;2 additionally, uncementedﬁxation
is not affected by any of the possible complications associatedwith cementedﬁxation like
third body wear and bone cement implantation syndrome.2,3 Despite these beneﬁts,
instability of uncemented joint replacements was a major drawback that prevented their
diffusion.4Modern designs have solved this problem and now these two ﬁxationmethods
are used in a similar proportion of cases worldwide (although their relative popularity
varies in different countries) and have similarly good clinical outcomes.4
Aseptic loosening is a severe bone loss (osteolysis) in the tissue surrounding the
implant and it is a consequence of a prolonged inﬂammation;5 it is the most likely
cause of revision surgery for both hip6 and knee7 and it is responsible for about
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40% of all revision procedures.8 Hence, the development
of anti-inﬂammatory drugs releasing devices has been seen
as tool in the ﬁght toward the reduction of arthroplasty
failure9,10 with the objective of improving on the current
NICE guidelines that have set a maximum rate of revision
after 10 years for the failure of 10%.11
The direct release of anti-inﬂammatory drugs from the
surface of cementless devices has been suggested as a
strategy to reduce the risk of aseptic loosening.12,13 The
administration of anti-inﬂammatory drugs does not treat
osteolysis but aims at reducing the periprosthetic inﬂam-
mation that leads to bone loss and consequent aseptic
loosing of the device.14
Dexamethasone (DEX) is a well known anti-inﬂamma-
tory steroidal drug widely used in clinical practice15,16 to
reduce inﬂammation.17 It is not water soluble, but the
esteriﬁcation with phosphate groups results in dexametha-
sone phosphate (DEX-P) that is highly water soluble and
is the main component of the medical formulations con-
taining DEX.
Layer-by-layer (LbL) is a self-assembly technique
employed to produce a coating and it relies on the alternated
deposition of positively and negatively charged polymers
(polyelectrolytes) through electrostatic attraction.18–22 LbL
has found medical applications when biocompatible polyelec-
trolytes are employed. LbL can be also used to release a drug
from the coating, replacing one of the polyelectrolytes with the
target molecule, whose only requirement is the presence of
electrostatic charges. Additionally, to prolong the release of
the target molecule, simply more layers are required.
Scalability and ease of fabrication of LbL coating are further
advantageous characteristics of such technique.18–22 The
deposition of antibiotics on surfaces using LbL enabled pro-
longed release of these drugs.23,24 Controlled release of DEX
from titanium surfaces has not been satisfactorily achieved as
the direct conjugation did not sustain release for more than a
few days.25 In this work, such steroidal drug was embedded
into a dissolvable coating made using alginate and a polymer
belonging to the class of poly-beta-amino-esters (PBAEs).26
Titanium nanoparticles were used as a model material for
titanium surfaces in light of their high surface/volume ratio
and identical chemical structure. The developed material was
characterized and the released drug anti-inﬂammatory activity
monitored against human monocytes and macrophages; cyto-
compatibility was assessed against human osteoblast and
ﬁbroblasts. Our research was driven by the following hypoth-
esis: DEX could be embedding in coatings through the use of
negatively charged, and water soluble, phosphate form of the
drug (DEX-P), taking advantage of the negative charge exhib-
ited by DEX-P; controlled and prolonged release of DEX
would be achieved through LbL; anti-inﬂammatory activity
of DEXwould be retained once released from the coatings and
no detrimental effects on osteoblast and ﬁbroblast cells would
be caused by the coatings activity.
Experimental
Chemicals
Titanium (IV) oxide (Anatase, <25 nm, 99.7%),
(3-Aminopropyl) triethoxy-silane (APTS, 99%), PBS
tablets, sodium acetate trihydrate (≥99%), DEX, DEX-P,
1,6 hexanediol diacrylate and piperazine were purchased
from Sigma-Aldrich, UK. HPLC grade acetonitrile, glacial
acetic acid and toluene were purchased from Fisher, UK.
All other chemicals were reagent grade, stored according
to manufacturer’s guidelines and used as received.
Polymer synthesis
Amino terminated poly-beta-amino esters, denoted as
POLY in the text, were synthesized by mixing 1,6 hexa-
nediol diacrylate and piperazine in DCM with piperazine
excess (molar ratio acrylate:amine 1:1.1). The reaction
was carried out at 50°C for 48 hrs and the polymers
recovered by pouring the reaction mixture in about ten
times volumes of diethyl-ether followed by vacuum
drying.27
Nanoparticles preparation
Surface functionalization of titanium oxide
nanoparticles
Titanium oxide nanoparticles were functionalized with
amino groups (Ti-O-NH2) via silanation in toluene.
Brieﬂy, the particles were dispersed in toluene containing
APTS for 24 hrs followed by repeated centrifugation/
washing.25
LbL coating technique
The amino ﬁctionalized titanium nanoparticles were
coated with polyelectrolyte multilayers. The layers con-
sisted of different numbers of a repeating sequence of
alginate, POLY, DEX-P and POLY. One sequence contain-
ing these four layers was termed quadruple layers, up to
ten quadruple layers were coated on the titanium nanopar-
ticles, named as Qn where n represents the number of
quadruple layers. The concentrations used were: 2 mg/
mL for sodium alginate and POLY, and 10 mg/mL for
DEX-P.27
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Nanoparticles surface and material
characterization
Transmission electron microscopy – particle size
determination
Images of particles were obtained using a Zeiss 902 trans-
mission electron microscope (TEM) operating at a voltage
of 80 kV. The aqueous dispersion of the particles was
drop-cast onto a carbon-coated copper grid, and grid was
dried at room temperature (20ºC) before loading into the
microscope (direct deposition). The average particle size,
size-distribution and morphology analysis of the samples
were carried out from at least ten non-overlapping ﬁelds of
view transmission electron micrographs using ImageJ for
Windows (Version 1.50i).
Thermogravimetric assay (TGA)
TGA was performed using a Perkin-Elmer TGA 4000
instrument. Coated nanoparticles were initially weighed
and heated from 50°C to 800°C with a heating rate of
10°C/min. Weight loss percentage of each sample at
100°C and 800°C was determined relative to initial
weight of the sample. Organic and inorganic content
was determined by subtracting the point at initial weight
loss (%) up to when the line plateaus (approximately
around 800°C).
DEX release quantiﬁcation
DEX release was measured by dispersing the DEX-coated
nanoparticles (10 mg) into 1 mL of a buffer media (acetate
buffer pH=5, and phosphate buffer pH=7.3) and incubated
at 37°C in Eppendorf.
Daily, the suspension was centrifuged at 4000 g for 10
mins at room temperature; the supernatant was withdrawn
for quantiﬁcation and the mediumwas replaced with an equal
volume of fresh buffer and the nanoparticles resuspended.
The amount ofDEX/DEX-P released from the coating layer
was determined using reverse-phase High Performance Liquid
using an Agilent Technologies® HPLC (1100 series) equipped
with a Waters-Spherisorb ODS2 column (Pore size – 80 Å, 5
µm, and packing dimension of 4.6mm×150mm). The injection
volume was 10 µL. The mobile phase was a mixture of PBS-
acetonitrile-glacial acetic acid 70:26:4 at a ﬂow rate of 1 mL/
min; a UV detector at 244 nm was employed.
Stock solutions of DEX-P and DEX with a concentra-
tion of 1 mg/mL were prepared separately and a series of
standards ranging from 0.4 to 250 µg/mL were prepared
for calibration.
Cells growth
Human monocytic leukemia cells (THP-1) and human
osteoblast cells (Saos-2) were obtained from ATCC and
grown in RPMI-1640 medium supplemented with 10%
heat-inactivated FBS and 1% penicillin – streptomycin
(PS) (Gibco by Life Technologies, USA). Human dermal
ﬁbroblast cells were kindly supplied by Prof. Stephens28
from Cardiff University and grown in Minimum Essential
Medium Eagle supplemented with 10% heat-inactivated
FBS and 1% PS (Gibco by Life Technologies). All types
of cells were incubated at 37°C in a humidiﬁed 5% CO2-
95% air atmosphere. Media were changed twice per week.
Differentiation of THP-1 monocytes to macrophages
To initiate the differentiation of monocyte-derived macro-
phages, 30 ng/mL of phorbol-12-myristate-13-acetate
(PMA, Sigma-Aldrich) was added to the RPMI-1640 med-
ium (10% FCS, 1% PS) for 3 days, where human mono-
cytic leukemia cells (THP-1) were grown in suspension.
Then, adhered monocyte-derived macrophages were
grown in RPMI-1640 medium supplemented with 10%
heat-inactivated FBS and 1% PS (Gibco by Life
Technologies) at 37°C in a humidiﬁed 5% CO2 atmo-
sphere. Cell medium was changed twice per week.
Exposure of cells to release media containing drug
Media containing DEX released from the LbL-coated
nanoparticles was prepared from fresh nanoparticles sus-
pended in buffer pH=7.3 as described in the release experi-
ment protocol; after incubation for 24 hrs at 37°C, the
suspension was centrifuged at 4000 g for 10 mins at
room temperature. The supernatant was withdrawn and
passed through 0.22-µm syringe ﬁlter for sterilization;
DEX concentration in this solution was 3 mg/L. A solution
of DEX-P containing an equivalent concentration of DEX
to that in the release buffer from LbL-coated nanoparticles
was prepared in buffer pH=7.3 and passed through 0.22
µm syringe ﬁlter. These two solutions were added to fresh
medium (1:9) to prepare solutions containing 0.3 mg/L
of DEX.
Cells were seeded in 96-well plates (Thermo Fisher
Scientiﬁc, Denmark) at a density of 5×104 cells per well
and incubated for 24 hrs at 37°C in a humidiﬁed 5% CO2
atmosphere to allow cell attachment. After removing the
media and washing the cells with sterile PBS, cells were
incubated for 3 hrs at 37°C in a humidiﬁed 5% CO2
atmosphere with release media from nanoparticles or
media containing DEX-P to an equivalent amount of
Dovepress Alotaibi et al
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DEX. The cells incubated in cell medium only with neither
24 hrs solute of nanoparticles nor lipopolysaccharides
(LPS) were used as blank control.
1 mg/L of LPS (Sigma-Aldrich) was added to the cells
in each well when required. The experiments were per-
formed in triplicate wells to evaluate the cytokines pro-
duced by cells and cell mitochondrial activity at two time
points, 6 and 24 hrs.
Biological test
MTT
MTT assay was conducted to measure human macro-
phages (THP-1), human osteoblasts (Saos-2) or ﬁbroblasts
mitochondrial activity post-exposure to DEX-coated tita-
nium nanoparticles after 1, 2 and 3 days exposure.24
IL-6 and tumor necrosis factor alpha (TNFα)
The amount of IL-6 and TNFα released by activated and
nonactivated THP-1 cells in the media after exposure to
LPS and DEX for 6 and 24 hrs was determined using
appropriate ELISA kit (Sigma, UK) according to manu-
facturer’s recommendations. The concentration of the
inﬂammation markers was performed by absorbance at
450 nm with (TNFα) or without reference wavelength at
650 nm (IL-6) in a multiwell microplate reader (LT-
5000MS ELISA reader, Labtech). Calibration curves
were obtained at each measurement to reduce variability
between experiments.
Epiﬂuorescent imaging
Cells were ﬁxed with 3.7% (w/v) formaldehyde in PBS at
room temperature for 5 mins and, then, permeabilized with
0.1% Triton X-100 for further 5 mins at room temperature.
F-actin cytoskeleton was stained with 50 mg/L of tet-
ramethyl rhodamine B isothiocyanate-conjugated phalloi-
din (Sigma-Aldrich, St. Louis, MO, USA) for 40 mins at
room temperature, followed by incubation with 5 mg/L of
trihydrochloride Hoechst 33342 (Thermo Fisher Scientiﬁc,
Eugene, OR, USA) for 10 mins in the dark to stain cells
nuclei. Samples were then washed with PBS, mounted and
examined using LSM 880 upright confocal laser scanning
microscope with Airyscan (Zeiss, Oberkochen, Germany)
with a 63× magniﬁcation objective. The following settings
were employed to excite the dyes and acquire the images:
λex 540–545 nm and λex 340 nm; λem 570–573 nm and λem
488 nm for tetramethyl rhodamine B isothiocyanate-con-
jugated phalloidin and Hoechst, respectively. The obtained
images were processed using ZEN imaging software
(Zeiss).29
Statistical analysis
One-way ANOVA was performed to assess the statistical
signiﬁcance of results between groups at a level p<0.05.
All data were expressed as mean±SD from at least three
independent values.
Results
TEM and particles size
Particles appeared cubical and spherical-like shaped
(Figure 1A–C) with relatively narrow distributed dia-
meters (Table 1). LbL did not noticeably impact the size
of the particles; however, after 10 quadruple layers, some
particles agglomeration could be observed.
Thermogravimetric analysis (TGA)
As visible in Figure 1D, the thermograms of all coated nano-
particles showed a plateau from around 650°C that is due to
the inorganic fraction (in this work made of TiO2) of the
nanoparticles remaining after the organic components have
been burnt.30,31 However, the mass loss at this point does not
correspond entirely to the amount of deposited polyelectrolyte
and drug as the weight loss occurring around 100°C is due to
the vaporization of entrapped water not a result of degradation
of organic compounds (alginate/POLY/DEX-P); therefore,
this mass loss needs offsetting in the calculations.32
The organic content (Table 2) of uncoated TiO2 (bare)
nanoparticles was the lowest (1.4±0.2%); while after amino
functionalization, the particles presented 4.2±0.9% of organic
fraction. Moreover, in LbL-coated particles, the weight loss at
800°C depended on the number of quadruple layers deposited,
from the highest for Q10 (17.5±1.4%) and the lowest for Q1
(6.6±0.4). As the organic content is a depended on the ﬁlm
thickness, Q10 was the highest ﬁlm coating, followed by Q7,
Q5, Q3 and Q1.
Drug loading
The amount of DEX loaded on the particles increased with
increasing number of quadruples layers deposited (Table 3),
starting from 0.021 mg DEX per mg of particles (2.1% w/w)
after one quadruple layers to 0.044 mg DEX per mg of
particles (4.5% w/w) when 10 quadruples layers were
deposited.
Alotaibi et al Dovepress
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DEX release quantiﬁcation
The amount of DEX released from the LbL-coated Ti-O-NH2
surfaces monotonically increased with time and overall the
entire amount of loaded drug was released at pH=5 regardless
of the number of quadruple layers deposited while at pH=7.3
not all the loaded drug was released; the amount of DEX
remained entrapped in the coating decreased with increasing
number of quadruple layers deposited. DEX was detectable in
the release media for longer periods of time with increasing
numbers of quadruple layers; moreover, drug release was
detectable for up to 20–30 days for both pH conditions
(Figure 2).
At pH=7.3, DEX was detected in the release buffer for up
to 25 days compared to 30 days for drug release at pH=5; the
same pattern (longer release at pH=5 than pH=7.3) was
observed for all the particles investigated regardless of number
of layers. Furthermore, the total amount of DEX released was
higher at pH=5 than the one released at pH=7.3 for compar-
able numbers of quadruples layers.
In-vitro inﬂammation model: LPS-
activated human monocytes and
macrophages
Mitochondrial activity
Cellular mitochondrial activity of macrophages after expo-
sure for 6 and 24 hrs to particle release buffer containing
0.3 mg/L of DEX or media containing and equivalent
amount of steroidal drug as DEX-P was assessed
Table 2 Percentage of organic material in multi-layered DEX-
LbL-loaded Ti-O-NH2 surface after addition of various quadruple
layers (Q1, Q3, Q5, Q7 and Q10)
Nanoparticles Organic content (%)
Bare particles 1.4±0.2
TiO-NH2 4.2±0.9
Q1 6.6±0.4
Q3 9.7±0.6
Q5 12.8±0.8
Q7 15.7±0.9
Q10 17.5±1.4
Abbreviations: DEX, dexamethasone; LbL, layer-by-layer.
Figure 1 Example of transmission electron microscopy images of (A) bare TiO2 nanoparticles, (B) amino functionalized (TiO2-NH2) nanoparticles and (C) LbL coated
(Q10). Bar represents 100 nm. (D) Thermograms of different LbL-DEX-coated Ti-O-NH2 substrate.
Abbreviations: DEX, dexamethasone; LbL, layer-by-layer.
Table 1 Average diameter size of TiO2 nanoparticles bare, after
functionalization and LbL deposition determined from TEM images
Sample Average size (nm)±SD
TiO2-particles 34±5
Amino-functionalized particles 34±6
Q10 40±8
Dovepress Alotaibi et al
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employing MTT assay and it did not reveal any detrimen-
tal effect (p>0.05) (Figure 3).
Inﬂammation markers (IL-6 and TNFα)
Activated human monocytes (macrophages) did not pro-
duce either noticeable amount of IL-6 or TNFα when not
exposed to LPS. When inﬂammation was induced, IL-6
reached ~1.2 ng/mL and ~1.4 ng/mL after 6 and 24 hrs of
exposure (Figure 4A–B); similarly TNFα concentration was
about ~30 and ~33 ng/mL after the same exposure (Figure
4C–D). The addition of DEX-P suppressed IL-6 production
to about a third after both 6 and 24 hrs; TNFα concentration
was reduced to half after 6 hrs and about a third after 24 hrs.
The use of an equivalent dose of DEX release from LbL
coating had similar reduction patterns for both inﬂamma-
tion markers but the efﬁcacy of the release drug was about
20–30% inferior to pure DEX (p<0.05).
The concentration of both inﬂammationmarkers (Figure 4)
released by human monocytes (non-activate) was lower com-
pared to macrophages, but the same pattern was observed with
release media containing DEX being capable of reducing the
levels of inﬂammation as pure DEX-P.
Cell morphology
Additionally, cell morphology and cytoskeletal properties
were evaluated by staining actin rings using confocal
microscopy (Figure 5). The results showed that, after 24
hrs growth in media without LPS and DEX (Figure 5A),
the human macrophages were spread over the surface
demonstrating a regular morphology. LPS exposure
(1 µg/mL) induced a reorganization in actin distribution
of the macrophages resulting in evident difference in cell
morphology: cells showed an oval-shaped conﬁguration
Table 3 DEX loading on multi-layered LbL-coated Ti-O-NH2
nanoparticles after addition of various quadruple layers (Q1,
Q3, Q5, Q7 and Q10)
Quadruple layers DEX loading (mg DEX/mg of NP)
Q1 0.021±0.004
Q3 0.025±0.004
Q5 0.032±0.005
Q7 0.033±0.006
Q10 0.045±0.006
Abbreviation: DEX, dexamethasone.
Figure 2 Cumulative release of DEX from LbL-Ti-O-NH2 surfaces at pH=5 (A) and pH=7.3 (B) for different number of quadruple layers (Q1, Q3, Q5, Q7 and Q10).
Abbreviations: PBAE, poly-beta-amino-ester; DEX-P, dexamethasone phosphate.
Alotaibi et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Nanomedicine 2019:147314
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
25
1.
25
4.
47
 o
n 
10
-S
ep
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
(Figure 5B), after addition of DEX the cell size increased
remaining oval shape (Figure 5C-D).
Safety assessment for orthopedic
application using osteoblasts (Saos-2) and
ﬁbroblasts
Mitochondrial activity
The mitochondrial activity of human osteoblasts and ﬁbro-
blasts exposed to DEX-P or the equivalent dose in release
buffers at pH=7.3 increased with exposing time (Figure 6).
No difference was observed when comparing control cells to
either DEX-P or DEX in release buffers (p>0.05) for osteo-
blasts; while for ﬁbroblasts no difference was detected
between DEX-P and DEX released from LbL coatings
(p>0.05); although both these were lower than the control.
Cell morphology
Osteoblast cells appeared spread with well organized actin
ﬁlaments regardless of the presence of LPS, DEX-P or
DEX from release buffers (Figure 7).
Similarly, the organization of the actin ﬁlaments in
ﬁbroblast cells was unaffected by the presence of LPS,
DEX-P or DEX from release buffers (Figure 8).
Discussion
We successfully developed novel LbL coatings for the release
of anti-inﬂammatory drugs from uncemented joint replacement
devices as a preventive approach to aseptic loosening. The
properties of these materials were determined to establish, not
only the successful preparation of the coatings and the desired
drug release proﬁle, but also the active reduction of the inﬂam-
matory process and the absence of major cytotoxic effects on
the various types of cells thematerials would be in contact with.
The size of bare particles determined was in agreement
with themanufacturer stated dimensions; amino functionaliza-
tion did not impact on the nanoparticles size, while the small
size increase calculated fromTEM images observed after coat-
ing with ten quadruple layers is consistent with polyelectrolyte
layers thickness under a few nanometers, similar to that
reported in other studies.27,33 As observed in other studies,
polyelectrolyte deposition on nanoparticles surfaces originates
Figure 3 Mitochondrial activity of activated (A) and non-activated (B) THP-1 cells exposed to media containing DEX-P or elutes from DEX released from LbL assembly for
6 and 24 hrs. LPS concentration of 1 µg/mL.
Abbreviations: LPS, lipopolysaccharides; LbL, layer-by-layer; DEX, dexamethasone; DEX-P, dexamethasone phosphate.
Dovepress Alotaibi et al
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agglomeration as the polyelectrolytes can deposit simulta-
neously over more than one particle during LbL assembly.34
These aggregates during subsequent layer deposition behave
as one individual particle leading to further agglomeration.
However, agglomeration appears to be minimal as LbL proto-
col was optimized to minimize such occurrence through poly-
electrolytes excess.
The amount of organic content on the surface of multi-
layered DEX-LbL loaded Ti-O-NH2 particles, after the deposi-
tion of each quadruple layer (alginate, POLY, DEX and algi-
nate) was evaluated by TGA (Figure 1D). Thermogravimetric
assay is typically conducted to conﬁrm and quantify the attach-
ment of organic molecules on surfaces either by conjugation35
or LbL.27 The organic fraction for the amino functionalized
nanoparticles (Table 2) was the results of the amino silanol
conjugating to the titanium surfaces; moreover, the organic
fraction increased with growing number of quadruple layers:
Q1, Q3, Q5, Q7, Q10 (Table 2). The organic content of the
nanoparticles after each quadruple layer observed in this work
was similar to LbL-coated silica nanoparticles containing
gentamicin.27 The amount was almost linear with the number
of quadruple layers up to Q7 but the rate of organic fraction
deposition decreased after this, because, as already seen in
TEM images, LbL is progressively hindered by agglomeration
and the available surface diminish accordingly.
In-vitro release studies were performed in buffers at two
different pH values to simulate different joint conditions:
healthy joints (pH=7.3)36 and inﬂamed joints, which are asso-
ciated with local acidosis (pH=5).37 Only DEX-P and not
DEX was detected in both the release media (pH=5 and
pH=7.3). Drug release from LbL constructs is the sum of
two simultaneous and independent processes; the progressive
detachment of the coating layers (delamination) and the diffu-
sion of the drug through the deposited layers.21 The kinetic of
the two phenomena depends on the nature of the polyelec-
trolytes employed and pH;27 these two parameters directly
Figure 4 IL-6 expression of activated (A) and non-activated (B); TNFα expression of activated (C) and nonactivated (D) THP-1 cells post-exposure to media containing
DEX-P or elutes from DEX released from LbL assembly for 6 and 24 hrs. LPS concentration of 1 µg/mL was used. (* represents signiﬁcant differences p<0.05)
Abbreviations: DEX-P, dexamethasone phosphate; LbL, layer-by-layer; DEX, dexamethasone; LPS, lipopolysaccharides; TNFα, tumor necrosis factor alpha.
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inﬂuence the hydrolysis kinetic of the polyelectrolytes, that
governs the delamination process, and the electrostatic attrac-
tions between layers that control the drug diffusion
coefﬁcient.21,27 Moreover, if diffusion is the predominant
mechanism of release the proﬁle exhibits an exponential beha-
vior with the highest drug release at the beginning that gradu-
ally drops to zero. On the contrary, pure delamination provides
a zero-order kinetic of release (constant rate until the LbL is
fully degraded).21,27 The release proﬁles observed in this work
(Figure 2) are attributable to release mechanism dominated by
diffusion, similar proﬁles were observed for other LbL coat-
ings prepared with the positive charged antibiotic
gentamicin18,27 or an osteoinductive protein.38 However,
DEX-P exhibited higher release at pH=5 than pH=7.3 while
gentamicin exhibited the opposite behavior.27 Higher DEX
release kinetic in acidic conditions compared to neutral were
also observed39 but determined by the hydrolysis of the ester
bond employed to conjugate the steroid. Since only DEX-P
was observed in the release buffers, the opposite impact of pH
on the release of DEX-P and gentamicin can be assumed to
depend on the charge of the two drugs at the pHs tested. POLY
is almost completely deprotonated at pH=7.3, with a charge
close to zero, while in mild acidic conditions (pH=5) is fully
protonated and positively charged; DEX-P acid groups are
deprotonated in both conditions and the drug is negatively
charged, analogously alginate is negatively charged in both
conditions; both molecules are more negatively charged at
pH=7.3 than pH=5. POLY hydrolysis is slow at pH=5,27
more a month to reach a 80% reduction of the polyelectrolyte
molecular weight, thus higher delamination does not contri-
bute to the release of DEX-P at pH=5 as it is also revealed by
the release proﬁle that is not zero order. Because of the
different protonation levels of the LbL components, it can be
hypothesized that diffusion of DEX-P deposited in the inner
layers of the coatings would be electrostatically hindered at
pH=7.3 more than at pH=5. POLY can counteract the negative
charges of alginate only in acidic conditions as it is almost
neutral at pH=7.3 (Figure 2) hence DEX-P molecules face
more electrostatic repulsion from alginate at pH=7.3. This also
explains the small impact of the number of deposited quad-
ruple layers on the overall drug release observed at pH=7.3
(Figure 2).
Moreover, drug release had been observed for about 4
weeks and this length of time is compatible with the
Figure 5 Actin staining epiﬂuorescent images of human macrophages (A) LPS- DEX-; (B) LPS+ DEX-; (C) LPS+ DEX-P and (D) LPS+ DEX from release buffer after 24-hr exposure
assessed by confocal microscopy. Actin rings and nuclei of cells were stained with phalloidin-FITC and DAPI, respectively; arrows indicate pseudopods. Bar corresponds to 20 µm.
Abbreviations: LPS, lipopolysaccharides; DEX, dexamethasone; DEX-P, dexamethasone phosphate.
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requirements to prevent the acute host inﬂammatory reac-
tion that occurs immediately after device implantation.
This reaction is due to both the injury tissues undergo
during surgery to place the device and the immunological
response to the material itself.40 Acute host inﬂammatory
reaction can result in difﬁcult device integration with
compromised functionality and longevity.41
Inﬂammation is accompanied by the release of numerous
makers in the surrounding tissues (ILs such as IL-6 and
TNFα), thus their quantiﬁcation is employed for diagnostic
purposes, including aseptic loosening.42–44 These inﬂamma-
tion markers induce both osteoclast differentiation and inhibit
osteoblast differentiation resulting in an overall bone loss;
furthermore, they are also responsible for attracting further
macrophages, osteoclasts and lymphocytes to the site aggra-
vating the inﬂammation.45 Both monocytes and macrophages
are known to release ILs and TNFα during inﬂammation46 and
such human monocytes and activated human monocytes
(THP-1)-derived macrophages, as model human
macrophages, were used in this study to test the anti-inﬂam-
matory properties of the coatings. LPS concentration of 1 µg/
mL is routinely employed to simulate inﬂammation in human
macrophages47,48 while IL-6 and TNFα were chosen to quan-
tify the inﬂammation process as they are common markers
employed in aseptic loosening research.49,50 Cells were
exposed to LPS and to either DEX-P or the same drug dose
using the elutes collected from the DEX release studies at
pH=7.3 to conﬁrm that the anti-inﬂammatory activity of
DEX, on inﬂammation markers such as TNFα and IL-6, was
retained when released from the LbL construct. The elutes
from the drug release studies performed at pH=5 were not
considered due to the low cellular viability they caused as
determined in preliminary studies (date not shown). As we
have shown (Figure 2) that DEX concentration in the release
media varied according to the number of layers deposited onto
the Ti-O-NH2 surfaces, only elutes from DEX released from
10QL assembly were used as maximum concentration of
released DEX was obtained.
LbL coatings release not only DEX but also polyelectro-
lytes or the products of POLY hydrolysis, therefore we deter-
mined whether both DEX activity was retained once released,
and LbL decomposition products potential toxicity and
inﬂammatory activity. DEX activity once released was mar-
ginally reduced compared to the equivalent amount of DEX-P
likely as the drug was deposited and not conjugated to the
surface, thus avoiding reactions for DEX active groups.
Beside IL-6 and TNFα production (Figure 4), LPS stimu-
lation (1 µg/mL) was shown to induce signiﬁcant changes on
the cytoskeletal properties andmorphology of the cells (Figure
5) compared to the untreated cells (control group). Multiple
pseudopods with abundant actin ﬁlaments were clearly visible
only on cells exposed to LPS; thesemembrane features did not
disappear when DEX was added. Similar images were pre-
sented by Liu et al51 and Qin et al.49 As monocytes/macro-
phages phagocytosis is key in their immunological activity,
structural changes may have negative impacts on monocytes
ability to perform the assigned tasks.52
The development and evaluation of any new biomaterial
must comprise not only the assessment of functionally to the
desired level, but also the demonstration of no adverse effects
caused to tissues and cells that the material will be in contact
with. Osteoblasts are the fundamental cells of bones and they
are routinely employed in in-vitro testing of novel orthopedic
materials,53,54 while ﬁbroblasts are present in connective
tissues.55 Moreover, the impact of the coating on human
monocytes (THP-1) and derived macrophages was also
determined to exclude drug toxicity toward these cell types.
Figure 6 Mitochondrial activity of Saos-2 (A) and ﬁbroblasts (B) cells exposed to
media containing DEX-P or elutes from LbL assembly for 1, 2 and 3 days expressed as %
of uncoated nanoparticles. (* represents signiﬁcant differences compared to release
from uncoated nanoparticles p<0.05).
Abbreviations: DEX-P, dexamethasone phosphate; LbL, layer-by-layer.
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It was not possible to grow cells directly onto the LbL-coated
surfaces as we employed titanium nanoparticles as a model
for titanium devices; hence, we tested the response of already
established osteoblast cultures to media containing either
DEX-P or released DEX to the response to sterile PBS.
Moreover, the tests were conducted only from release buffer
pH=7 as the acidic buffer (pH=5) exhibited toxic activity.
DEX released from the LbL coating did not negatively
impact osteoblasts (Figure 6), ﬁbroblast (Figure 7) and, as
such, these materials are not inferior to standard titanium
in regards to osteoblasts growth. Furthermore, mitochon-
drial activity of monocytes and macrophages was not
affected by the coatings. Because titanium exhibits sufﬁ-
cient cytocompatibility toward osteoblasts, it was not
necessary for the LbL coating to improve such properties
and non-inferiority was deemed sufﬁcient. POLY belongs
to a class of known biocompatible polyelectrolytes hence
the lack of toxic was expected.
In this work, we employed nanoparticles as model for
implant surfaces, the next development stage will be the
assessment of whether coatings on larger surfaces (i.e. cou-
pons) would still provide an effective drug dose in light of the
lower surface area/unit volume or the amount of quadruple
layers necessary to achieve the required drug concentration.
Conclusion
Longevity of joint replacement devices is severely impacted
by inﬂammatory processes that can lead to bone loss and
aseptic loosening of the prosthesis. We have successfully
controlled the release of DEX (a widely used anti-inﬂamma-
tory steroidal drug) for about a month. This material did not
impact on osteoblasts or ﬁbroblasts proliferation and the anti-
inﬂammatory activity of the realized drug was retained. These
materials, therefore, appear a potential tool for reducing the
number of revision surgeries necessary when aseptic loosen-
ing develops. Uncemented hip replacement devices have a
porous or textured surface to allow mechanical interlocking
with the bone; hence, during insertion only the outer part of the
surface contacts the bone. Because of this, our proposed coat-
ing depositedwithin the porous surfacewill not be subjected to
Figure 7 Actin staining epiﬂuorescent images of human osteoblast (Saos-2) (A) no DEX; (B) LPS; (C) LPS+ DEX-P and (D) DEX from release buffer after 24-hr exposure
assessed by confocal microscopy. Actin rings and nuclei of cells were stained with phalloidin-FITC and DAPI, respectively. Bar corresponds to 20 µm.
Abbreviations: LPS, lipopolysaccharides; DEX, dexamethasone; DEX-P, dexamethasone phosphate.
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friction and will remain unaffected by the handling and
mechanical actions associated with the surgery.
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